characteristics.text: 2013-04-01T17:02:48Z
characteristics.characteristic: ENA-FIRST-PUBLIC
characteristics.text: 2018-03-08T16:18:13Z
characteristics.characteristic: ENA-LAST-UPDATE
characteristics.text: SAMEA1713770
characteristics.characteristic: External Id
characteristics.text: Cancer Research UK Cambridge Institute
characteristics.characteristic: INSDC center name
characteristics.text: 2013-04-01T17:02:48Z
characteristics.characteristic: INSDC first public
characteristics.text: 2018-03-08T16:18:13Z
characteristics.characteristic: INSDC last update
characteristics.text: public
characteristics.characteristic: INSDC status
characteristics.text: ERS219098
characteristics.characteristic: SRA accession
characteristics.text: E-MTAB-1534:BIOPSY_3691
characteristics.characteristic: Submitter Id
characteristics.text: ArrayExpress
characteristics.ontologyTerms: http://www.ebi.ac.uk/efo/EFO_0009737
characteristics.characteristic: broker name
characteristics.text: epithelial
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/CL_0000066
characteristics.characteristic: cell type
characteristics.text: human
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/NCBITaxon_9606
characteristics.characteristic: common name
characteristics.text: Protocols: Tissue for ChIP-seq analyses was from patients who were treated at the Netherlands Cancer Institute.Three biopsies (14-gauge, 15 mm thick) were taken from each tumour, two of which where frozen with liquid nitrogen and one was formalin-fixed for direct clinical assessment. Tumour cell percentage was determined using Hematoxylin and Eosin (H&E), and tissue was only used for ChIP-seq analysis when tumour cell percentage was higher then 50%. All samples stained positive for Estrogen Receptor. Samples were processed and chromatin was extracted as described (Schmidt et al., Methods 48:3 pp240-248 2009) but with a number of modifications. During the immunoprecipitation, 100mg/ml glycogen (Invitrogen) or 20mg/ml recombinant histone 2B (M2505S; New England Biolabs) and 1mg/ml human mRNA (Invitrogen) was added as carriers for the ChIP. During the entire procedure, non-sticky eppendorf tubes were used (13-698-794; Fisher Scientific).
characteristics.characteristic: description
characteristics.text: breast cancer
characteristics.ontologyTerms: http://www.ebi.ac.uk/efo/EFO_0000305
characteristics.characteristic: disease state
characteristics.text: Homo sapiens
characteristics.characteristic: organism
characteristics.text: Homo sapiens
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/NCBITaxon_9606
characteristics.characteristic: organism
characteristics.text: breast
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/UBERON_0000310
characteristics.characteristic: organism part
characteristics.text: Homo sapiens
characteristics.characteristic: scientific_name
characteristics.text: female
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/PATO_0000383
characteristics.characteristic: sex
characteristics.text: BIOPSY_3691
characteristics.characteristic: title